CAS 845614-12-2: [4-[3-Fluoro-5-(trifluoromethyl)-2-pyridinyl]-1-piperazinyl][5-(methylsulfonyl)-2-[(1R)-2,2,2-trifluoro-1-methylethoxy]phenyl]methanone

Bitopertin R enantiomer (RG1678 R enantiomer) is the R-enantiomer of Bitopertin.

Bitopertin is a glycine reuptake inhibitor, which is sourced from the development of selective central nervous system agents. It works by inhibiting the glycine transporter type 1 (GlyT1), thereby increasing extracellular glycine levels, particularly in regions with high densities of NMDA receptors. This modulation of glycine levels plays a crucial role in enhancing NMDA receptor function, which is pivotal for synaptic plasticity and neurotransmission. The Bitopertin R enantiomer is being researched for its potential applications in treating disorders such as schizophrenia, where dysregulation of the glutamatergic system is implicated. By augmenting NMDA receptor activity, Bitopertin may help in ameliorating negative symptoms and cognitive deficits associated with the disorder. Ongoing studies aim to explore its efficacy and safety profile further, providing insights into its potential role in therapeutic interventions aimed at fine-tuning neurotransmitter systems. This makes it a promising candidate in the realm of neuropsychiatric drug development, with continued research necessary to fully elucidate its clinical benefits and limitations.